Bayer is exploring how Artificial Intelligence can be used to assess case reports relating to adverse drug events in relation to its medicines; further increasing the efficiency of pharmacovigilance operating model and case processing

Bayer is exploring how Artificial Intelligence can be used to assess case reports relating to adverse drug events in relation to its medicines; further increasing the efficiency of pharmacovigilance operating model and case processing: https://ift.tt/2qDrMGm Read more... https://ift.tt/2qDqivS